LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

Home・Stock List・Incyte Corp

Incyte Corp

Open

SectorHealthcare

97.28 -0.05

Buy Sell

Overview

Share price change

24h

Current

Min

96.02

Max

97.58

Key metrics
By Trading Economics
Income	4.1M 303M
Sales	-234M 1.3B
P/E Sector Avg	13.723 50.102
EPS	1.81
Profit margin	23.834
Employees	2,844
EBITDA	-47M 368M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+11.52% upside

Dividends
By Dow Jones
Next Earnings	28 Jul 2026

Market Stats
By TradingEconomics
Market Cap	362M 19B
Previous open	97.33
Previous close	97.28

News Sentiment

By Acuity

25%

75%

39 / 344 Healthcare

Incyte Corp Chart

Past performance is not a reliable indicator of future results.

Related News

27 May 2026, 21:33 UTC

Earnings

Correction to Salesforce 1Q Sales, Profit Rise Article

27 May 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 May 2026, 20:18 UTC

Earnings

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 May 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 May 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 May 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 May 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 May 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 May 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 May 2026, 21:29 UTC

Hot Stocks

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 May 2026, 21:08 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 May 2026, 21:02 UTC

Earnings

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 May 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 May 2026, 20:55 UTC

Earnings

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 May 2026, 20:48 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 May 2026, 20:45 UTC

Earnings

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 May 2026, 20:34 UTC

Acquisitions, Mergers, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 May 2026, 20:32 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 May 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 May 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 May 2026, 20:30 UTC

Earnings

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 May 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 May 2026, 20:22 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 May 2026, 20:16 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 May 2026, 20:13 UTC

Earnings

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 May 2026, 20:13 UTC

Earnings

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 May 2026, 20:13 UTC

Earnings

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 May 2026, 20:12 UTC

Earnings

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 May 2026, 20:12 UTC

Earnings

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Comparison

Price change

Incyte Corp Forecast

Price Target

By TipRanks

11.52% upside

12 Months Forecast

Average 108.29 USD 11.52%

High 135 USD

Low 75 USD

Based on 19 Wall Street analysts offering 12 month price targets forIncyte Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Incyte Corp - Dist in the past 3 months.

Sentiment

By Acuity

39 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation